# EDGAR Filing Document

**Accession Number:** 0001760903
**File Stem:** 0001493152-23-003247
**Filing Date:** 2023-2
**Character Count:** 11068
**Document Hash:** 54689c73c882f040f1a872bff3ef9bfa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-003247.hdr.sgml**: 20230201

**ACCESSION NUMBER**: 0001493152-23-003247

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230201

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230201

**DATE AS OF CHANGE**: 20230201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jupiter Wellness, Inc.
- **CENTRAL INDEX KEY:** 0001760903
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **IRS NUMBER:** 832455880
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39569
- **FILM NUMBER:** 23574848

**BUSINESS ADDRESS:**
- **STREET 1:** 1061 E. INDIANTOWN RD.
- **STREET 2:** STE. 110
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477
- **BUSINESS PHONE:** 561-325-0482

**MAIL ADDRESS:**
- **STREET 1:** 1061 E. INDIANTOWN RD.
- **STREET 2:** STE. 110
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CBD Brands, Inc.
- **DATE OF NAME CHANGE:** 20181206

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C., 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 1, 2023

**JUPITER WELLNESS, INC.**

(Exact name of registrant as specified in charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39569** | **83-2455880** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**1061 E. Indiantown Rd., Ste. 110, Jupiter, FL 33477**

(Address of principal executive offices) (Zip Code)

**(561) 244-7100**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | JUPW | The Nasdaq Stock Market LLC<br> (The Nasdaq Capital Market) |
| Warrants, each exercisable for one share of Common Stock at $8.50 per share | JUPWW | The Nasdaq Stock Market LLC<br> (The Nasdaq Capital Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On February 1, 2023, Jupiter Wellness, Inc. (the "Company") appointed Dr. Hector Alila as an additional director .

**Dr. Hector Alila, Director** served as one of our directors from February 2019 to December 2022. Dr. Alila brings 30 years of demonstrated scientific experience in product development and successful management leadership in biopharmaceutical industry. He is the Founding President and Chief Executive Officer of Esperance Pharmaceutical Inc., a clinical stage biopharmaceutical company that has successfully developed novel targeted cancer therapeutics currently in clinical development. Dr. Alila founded Esperance Pharmaceutical, Inc. in 2006. Prior to Esperance, Dr. Alila served as Senior Vice President of Drug Development at Protalex, Inc., where he led the development of a drug currently in clinical trials for treatment of autoimmune diseases. He was previously Vice President of Product Development at Cell Pathways, Inc., where he was responsible for the development cancer drugs, and a director of Biology/pharmacology at GeneMedicine, Inc., where he led product development of gene medicines. He also held several research, product development and management positions at SmithKline Beecham Pharmaceuticals. He obtained his Ph.D. in physiology and immunology from Cornell University.

**Item 7.01. Regulation FD Disclosure**

On February 1, 2023, Jupiter Wellness, Inc. (the "Company") issued a press release. A copy of the press release is furnished hereto as <u>Exhibit 99.1</u> and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

**Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release dated February 1, 2023](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 1, 2023

---

| | |
|:---|:---|
| **JUPITER WELLNESS, INC.** | **JUPITER WELLNESS, INC.** |
| By: | */s/ Brian John* |
|  | *Brian John* |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| **FINAL FOR RELEASE** | ![](ex99-1_001.jpg) |
|  | ![](ex99-1_001.jpg) |
| **Contact** | ![](ex99-1_001.jpg) |
| Jupiter Wellness, Inc. | ![](ex99-1_001.jpg) |
| 561-244-7100 | ![](ex99-1_001.jpg) |
| investors@jupiterwellness.com | ![](ex99-1_001.jpg) |
|  | ![](ex99-1_001.jpg) |
| **Release Date** | ![](ex99-1_001.jpg) |
| 2/1/2023 | ![](ex99-1_001.jpg) |

---

**Jupiter Wellness Reappoints Dr. Hector Alila to Board of Directors**

**JUPITER, FL / February 1, 2023 –** <u>Jupiter Wellness</u>, Inc. (Nasdaq: <u>JUPW</u>), a wellness company focused on hair, skin, and sexual wellness announced today that Dr. Hector Alila has rejoined its Board of Directors with the specific responsibility of building a Technical Advisory Board.

Dr. Glynn Wilson, Board Chairman said, "We are pleased to welcome Hector back to our Board. With our focus on new scientific and clinical programs, our immediate need is to build a top-tier team of technical advisors to review our R&D activities and scientific approaches."

Dr. Wilson continued, "Dr. Alila brings 30 years of experience in translating novel research into clinical programs and product opportunities. He was most recently at Esperance Pharmaceuticals where he guided the clinical development of novel targeted cancer therapeutics. With a Ph.D. in physiology and immunology, and a broad R&D background covering cancer, autoimmune disease, infectious diseases, and gene therapy, he will be pivotal in helping us establish an advisory group and moving Jupiter Wellness forward into clinical trials and working with the FDA."

**About Jupiter Wellness**

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The Company's product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements, and licensing royalties.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at <u>https://jupiterwellness.com/email-alerts/</u> and by following Jupiter Wellness on <u>Twitter</u> and <u>LinkedIn</u>.

**Media Contact**

Phone: 561-244-7100

Email: media@jupiterwellness.com

**Investor Contact**

Phone: 561-244-7100

Email: investors@jupiterwellness.com

**Forward-Looking Statements**

This communication contains forward-looking statements regarding Jupiter Wellness, including, the anticipated timing of studies and the results and benefits thereof. You can generally identify forward-looking statements by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the Company's current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond Jupiter Wellness' control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other risks and uncertainties affecting Jupiter Wellness, including those described from time to time under the caption "Risk Factors" and elsewhere in Jupiter Wellness' Securities and Exchange Commission (SEC) filings and reports, including Jupiter Wellness' Annual Report on Form 10-K for the year ended December 31, 2021, and future filings and reports by Jupiter Wellness. Moreover, other risks and uncertainties of which the combined company is not currently aware may also affect each of the companies' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by Jupiter Wellness on its website or otherwise. Jupiter Wellness undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date on which the forward-looking statements were made.

###